2435-36-1

Basic information

• Product Name: DIMETHYLNORCAMPHORATE
• Synonyms: DIMETHYLNORCAMPHORATE;1,3-Cyclopentanedicarboxylic acid dimethyl ester;Dimethyl=1,3-cyclopentanedicarboxylate;Cyclopentane-1,3-dicarboxylic acid dimethyl ester;Norcamphoric acid, dimethyl ester;1,3-Bis(methoxycarbonyl)cyclopentane;1,3-diMethyl cyclopentane-1,3-dicarboxylate;1,3-Cyclopentanedicarboxylic acid, 1,3-diMethyl ester
• CAS NO: 2435-36-1
• Molecular Formula: C₉H₁₄O₄
• Molecular Weight: 186.21
• Mol File: 2435-36-1.mol

Chemical Properties

• Boiling Point: 241℃
• Flash Point: 113℃
• Appearance: /
• Density: 1.135
• Vapor Pressure: 0.037mmHg at 25°C
• Refractive Index: 1.461
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly)
• CAS DataBase Reference: DIMETHYLNORCAMPHORATE(CAS DataBase Reference)
• NIST Chemistry Reference: DIMETHYLNORCAMPHORATE(2435-36-1)
• EPA Substance Registry System: DIMETHYLNORCAMPHORATE(2435-36-1)

Safety Data

• Hazardous Substances Data: 2435-36-1(Hazardous Substances Data)

Usage

Uses

Used in Research and Development:
DIMETHYLNORCAMPHORATE is used as an organic synthesis intermediate for the development of new compounds and materials. Its unique chemical structure allows for various reactions and modifications, contributing to the advancement of scientific knowledge and the creation of novel products.
Used in Pharmaceutical Industry:
DIMETHYLNORCAMPHORATE is used as a pharmaceutical intermediate, playing a crucial role in the synthesis of various drugs and medications. Its involvement in the production process helps in the development of new pharmaceuticals that can address specific health issues and improve patient outcomes.
Used in Chemical Production Process:
DIMETHYLNORCAMPHORATE is utilized in the chemical production process, where it serves as a key component in the manufacturing of various chemicals and chemical products. Its presence in the production process ensures the efficient synthesis of desired compounds, contributing to the overall efficiency and effectiveness of the chemical industry.

Synthesis

A 5-L, 3-neck, roundbottom flask was equipped with a mechanical stirrer, a J-KEM temperature controller, and a reflux condenser. The flask was charged with cyclopentane-l,3-dicarboxylic acid(357 g, 2.262 mol) and methanol (1.75 L). The solution was cooled to 7 °C using anice/water bath. Concentrated sulfuric acid (70 mL) was added dropwise over 30 minresulting in an exotherm up to 12 °C. The reaction mixture was heated to reflux andstirred for 16 h when TLC analysis (10 percent methanol/ethyl acetate) indicated that thereaction was complete. The reaction mixture was concentrated, redissolved in methyl- 179 -ATI-2514175vl tert-butyl ether, and washed with saturated aqueous sodium bicarbonate (2 x 150 mL) and brine (2 x 150 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated. The resulting clear oil was dissolved in hexane (2 L) and treated with a 2 N aqueous sodium hydroxide solution (950 mL) until the pH ~ 10. The layers were separated and the aqueous layer was extracted with hexane (4 x 1 L). The organic layers were combined, dried over sodium sulfate, filtered, and concentrated to provide 360 g (100percent) of dimethyl cyclopentane-l,3-dicarboxylate as a clear oil.

InChI:InChI=1/C9H14O4/c1-12-8(10)6-3-4-7(5-6)9(11)13-2/h6-7H,3-5H2,1-2H3

Upstream product

• 67-56-1 methanol 
• 4056-78-4 cyclopentane-1,3-dicarboxylic acid 
• 186581-53-3 diazomethane 
• 111138-52-4 (1S,3S)-Cyclopentane-1,3-dicarboxylic acid monomethyl ester 
• 80656-14-0 trans-1,2-cyclopentanedicarboxylic acid 
• 84545-00-6 3-(methoxycarbonyl)-cyclopentane-1-carboxylic acid 
• 498-66-8 norborn-2-ene 

Downstream Products

• 42145-38-0 dimethyl bicyclo<2.1.1>hexane-1,4-dicarboxylate 
• 116783-32-5 (-)-cyclopentane-1,3-dicarboxylic acid 
• 344294-32-2 methyl 3-formylcyclopentane-1-carboxylate 
• 58240-93-0 (+)-cis-(1R,3S)-3-hydroxymethyl-1-carbomethoxycyclopentane 
• 84545-00-6 3-(methoxycarbonyl)-cyclopentane-1-carboxylic acid 
• 1341037-89-5 2-(tert-butoxycarbonyl)-2-azaspiro[4.4]nonane-7-carboxylic acid 
• 1201186-85-7 methyl 4-((tert-butoxycarbonyl)amino)bicyclo[2.2.1]heptane-1-carboxylate 
• 1252672-35-7 4-(benzyloxycarbonylamino)bicyclo[2.2.1]heptane-1-carboxylic acid methyl ester 
• 15544-51-1 bicyclo<2.2.1>heptane-1,4-dicarboxylic acid 
• 1403865-38-2 benzyl 4-hydroxybicyclo[2.2.1]heptan-1-ylcarbamate 
• 737693-57-1 4-aminobicyclo[2.2.1]heptane-1-carboxylic acid 
• 1252672-36-8 4-(benzyloxycarbonylamino)bicyclo[2.2.1]heptane-1-carboxylic acid 
• 15448-77-8 4-carbomethoxybicyclo<2.2.1>heptane-1-carboxylic acid 
• 15448-76-7 dimethyl bicyclo<2.2.1>heptane-1,4-dicarboxylate 

Relevant articles and documents

Polycyclic amide derivative as CDK9 inhibitor, and preparation method and application thereof

The invention belongs to the technical field of polycyclic amide derivatives, and particularly relates to a polycyclic amide derivative as a CDK9 inhibitor, and a preparation method and application thereof. The polycyclic amide derivative shows excellent CDK9 enzyme inhibitory activity, and can be used for preparing drugs for treating cancers, especially hematologic cancers including acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, follicular lymphoma and the like and solid tumors, such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia and follicular lymphoma, including breast cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, pancreatic cancer, kidney cancer, stomach cancer, colorectal cancer, lung cancer and the like.

SMALL MOLECULE INHIBITORS OF THE JAK FAMILY OF KINASES

2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK.

Small Molecule Inhibitors of the JAK Family of Kinases

2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease.

IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES

2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease.

BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS

Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, or their use in therapy.

TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS

Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, or their use in therapy.

BIARYLETHER IMIDAZOPYRAZINE BTK INHIBITORS

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.

SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.

Design, synthesis, radiolabeling, and in vitro and in vivo evaluation of bridgehead iodinated analogues of N -{2-[4-(2-methoxyphenyl)piperazin-1-yl] ethyl}- N -(pyridin-2-yl)cyclohexanecarboxamide (WAY-100635) as potential SPECT ligands for the 5-HT1A receptor

Here we describe the design, synthesis, and pharmacological profile of 5-HT1A receptor ligands related to 1 (WAY-100635). The cyclohexyl moiety in 1 and its O-desmethylated analogue 3 were replaced by the bridgehead iodinated bridge-fused rings: adamantyl, cubyl, bicyclo[2.2.2]octyl, or bicyclo[2.2.1]heptyl. All analogues displayed a (sub)nanomolar affinity for the 5-HT1A receptor in vitro. Compounds 6b and 7b appeared to be selective for this receptor over other relevant receptors and could easily be iodinated with radioactive iodine-123. In humane hepatocytes, [ 123I]6b showed a low propensity for amide hydrolysis and a stable carbon-iodine bond. The biodistribution of [123I]6b and [ 123I]7b in rats revealed that the carbon-iodine bond was also stable in vivo. Unfortunately, the brain uptake and the specificity for both radioligands were significantly lower than those of the parent molecule 1. In conclusion, the designed tracers are not suitable for SPECT imaging.

HETEROBICYCLIC METALLOPROTEASE INHIBITORS

The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP- 13 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP- 13 inhibitors.